Corporate News

Concepta Plc (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market is pleased to announce it has agreed to supply the myLotus® product to Walgreens Boots Alliance (WBA) for women's fertility and hormone testing.

myLotus® the revolutionary home based, self-test product was launched in November 2018 with early  'trying to conceive' users providing personal video feedback and testimonials on their menstrual cycle hormone changes and hormone patterns ('signatures') enabling women to better understand their menstrual cycle and fertility journey (www.mylotus.com).

The supply agreement represents the first commercial partnership forming part of the Company's EU roll-out plans. myLotus® recently received CE-Mark certification and the agreement allows the Company to extend its UK relationship with 'Boots the Chemist' to other Walgreens Boots Alliance partners across EU markets (CE-Mark territories).

myLotus® empowers women to self-test their personalised hormone levels and identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app available in iOS and Android formats via the  www.mylotus.com website.

myLotus® is available to women who are planning to start a family or for those who have previously struggled to naturally conceive, enabling couples an alternative prior to considering more costly IVF treatment. The Company expects to release further hormone health and wellbeing tests to complement its fertility offering later this year.   

Matthew Walls, Chairman said: "We are delighted to work with such a respected British high-street brand and retailer and look forward to supplying myLotus® to Boots the Chemist to help improve the chances of a natural pregnancy. We are now preparing our EU market roll-out plans and will update the market in due course"

Enquiries:

The Company

Company:   www.conceptaplc.com,  Product: www.mylotus.com

Matthew Walls, Chairman

Tel: +44 (0) 1234 866601

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

Novum Securities

Colin Rowbury

+44 (0) 20 7399 9400

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Concepta Plc:

About Concepta Plc:  Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019. 

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.